Codexis, Inc. (CDXS): Price and Financial Metrics


Codexis, Inc. (CDXS): $5.60

0.02 (+0.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CDXS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CDXS POWR Grades

  • Quality is the dimension where CDXS ranks best; there it ranks ahead of 75.61% of US stocks.
  • The strongest trend for CDXS is in Quality, which has been heading up over the past 26 weeks.
  • CDXS's current lowest rank is in the Stability metric (where it is better than 12.3% of US stocks).

CDXS Stock Summary

  • The price/operating cash flow metric for CODEXIS INC is higher than 91.91% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of 95.15%, CODEXIS INC's debt growth rate surpasses 87.71% of about US stocks.
  • In terms of volatility of its share price, CDXS is more volatile than 93.06% of stocks we're observing.
  • Stocks that are quantitatively similar to CDXS, based on their financial statements, market capitalization, and price volatility, are SPCE, PXLW, VLN, LXRX, and TFFP.
  • CDXS's SEC filings can be seen here. And to visit CODEXIS INC's official web site, go to www.codexis.com.

CDXS Valuation Summary

  • In comparison to the median Healthcare stock, CDXS's EV/EBIT ratio is 228.4% lower, now standing at -10.4.
  • Over the past 154 months, CDXS's price/earnings ratio has gone up 9.7.

Below are key valuation metrics over time for CDXS.

Stock Date P/S P/B P/E EV/EBIT
CDXS 2022-12-05 2.9 2.5 -12.5 -10.4
CDXS 2022-12-02 2.8 2.4 -11.9 -9.9
CDXS 2022-12-01 2.8 2.4 -11.9 -9.8
CDXS 2022-11-30 2.7 2.3 -11.5 -9.5
CDXS 2022-11-29 2.5 2.1 -10.6 -8.5
CDXS 2022-11-28 2.5 2.1 -10.6 -8.6

CDXS Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -312.22%.
  • Its 3 year net income to common stockholders growth rate is now at -81.69%.
  • The 2 year revenue growth rate now stands at 80.71%.
Over the past 70 months, CDXS's revenue has gone up $83,880,000.

The table below shows CDXS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 132.717 7.027 -31.178
2022-06-30 135.016 -12.899 -18.942
2022-03-31 122.063 -19.013 -20.567
2021-12-31 104.754 -14.267 -21.279
2021-09-30 101.287 -16.419 -15.009
2021-06-30 82.903 -19.701 -23.347

CDXS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDXS has a Quality Grade of C, ranking ahead of 53.6% of graded US stocks.
  • CDXS's asset turnover comes in at 0.423 -- ranking 65th of 89 Chemicals stocks.
  • NGVT, GPP, and IFF are the stocks whose asset turnover ratios are most correlated with CDXS.

The table below shows CDXS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.423 0.782 -0.333
2021-03-31 0.406 0.787 -0.370
2020-12-31 0.424 0.801 -0.359
2020-09-30 0.461 0.831 -0.313
2020-06-30 0.479 0.819 -0.220
2020-03-31 0.457 0.796 -0.237

CDXS Price Target

For more insight on analysts targets of CDXS, see our CDXS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.50 Average Broker Recommendation 1.31 (Strong Buy)

CDXS Stock Price Chart Interactive Chart >

Price chart for CDXS

CDXS Price/Volume Stats

Current price $5.60 52-week high $35.35
Prev. close $5.58 52-week low $4.81
Day low $5.47 Volume 466,500
Day high $5.77 Avg. volume 904,220
50-day MA $5.67 Dividend yield N/A
200-day MA $10.42 Market Cap 367.85M

Codexis, Inc. (CDXS) Company Bio


Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company was founded in 2002 and is based in Redwood City, California.


CDXS Latest News Stream


Event/Time News Detail
Loading, please wait...

CDXS Latest Social Stream


Loading social stream, please wait...

View Full CDXS Social Stream

Latest CDXS News From Around the Web

Below are the latest news stories about CODEXIS INC that investors may wish to consider to help them evaluate CDXS as an investment opportunity.

Codexis Shelves Development Of Certain Internal Programs, Cuts Workforce

Codexis Inc (NASDAQ: CDXS) decided to discontinue investment in certain internal development programs, expand investment in high-potential development programs and reduce its workforce by approximately 18%. "Since joining as CEO three months ago, the leadership team and I have been carefully assessing our near- and long-term commercial opportunities with the goal of identifying the programs where we believe Codexis is best positioned to win. We are now ready to begin implementing our plan to enh

Yahoo | November 30, 2022

Codexis Provides Update on Prioritized Corporate Strategy

REDWOOD CITY, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced an update on the Company’s ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and greatest probability of success. As part of this plan, the Company has decided to discontinue investment in certain internal development programs, expand investment in high potential development prog

Yahoo | November 29, 2022

Codexis to Participate in Piper Sandler 34th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference, being held on November 29-December 1, 2022, in New York, New York. The fireside chat is taking place on Thursday, December 1, 2022, at 1:30 p.m. ET. A webcast of the discussion will be available in the Investor

Yahoo | November 16, 2022

Codexis Third Quarter 2022 Earnings: Beats Expectations

Codexis ( NASDAQ:CDXS ) Third Quarter 2022 Results Key Financial Results Revenue: US$34.5m (down 6.3% from 3Q 2021...

Yahoo | November 9, 2022

Codexis to Participate in Upcoming Healthcare Conferences

REDWOOD CITY, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management will participate in three upcoming investor conferences. The Stephens Annual Investment Conference on November 15, 2022, at 2:00 p.m. ET in Nashville, Tennessee – management will participate in an in-person fireside chat. The Stifel 2022 Healthcare Conference on November 16, 2022, at 1:50 p.m. ET in N

Yahoo | November 8, 2022

Read More 'CDXS' Stories Here

CDXS Price Returns

1-mo -3.95%
3-mo -24.32%
6-mo -38.86%
1-year -83.49%
3-year -63.94%
5-year -18.25%
YTD -82.09%
2021 43.24%
2020 36.52%
2019 -4.25%
2018 100.00%
2017 81.52%

Continue Researching CDXS

Here are a few links from around the web to help you further your research on Codexis Inc's stock as an investment opportunity:

Codexis Inc (CDXS) Stock Price | Nasdaq
Codexis Inc (CDXS) Stock Quote, History and News - Yahoo Finance
Codexis Inc (CDXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8539 seconds.